PMID- 26450220
OWN - NLM
STAT- MEDLINE
DCOM- 20170119
LR  - 20210504
IS  - 1554-6063 (Electronic)
IS  - 0145-7217 (Linking)
VI  - 41
IP  - 1 Suppl
DP  - 2015 Dec
TI  - Sodium-Glucose Cotransporter 2 Inhibitors in the Treatment of Type 2 Diabetes 
      Mellitus.
PG  - 5S-18S
LID - 10.1177/0145721715607643 [doi]
AB  - PURPOSE: The purpose of this review article is to provide guidance to clinicians 
      and diabetes educators regarding the use of sodium-glucose cotransporter 2 
      (SGLT2) inhibitors as a therapeutic option for the treatment of patients with 
      type 2 diabetes mellitus (T2DM). METHODS: The PubMed database was searched 
      through February 2015 to identify clinical trials and meta-analyses evaluating 
      the use of the SGLT2 inhibitors canagliflozin, dapagliflozin, and empagliflozin 
      administered as monotherapy or in combination with other oral antidiabetes drugs 
      or with insulin. RESULTS: SGLT2 inhibitors reduce hyperglycemia in an 
      insulin-independent manner by inhibiting the reabsorption of glucose into the 
      systemic circulation by the kidneys. In patients with T2DM, SGLT2 inhibitors 
      provide consistent reductions in glycated hemoglobin, fasting plasma and 
      postprandial glucose, body weight, and blood pressure when used as monotherapy or 
      in combination with other oral antidiabetes agents or with insulin. SGLT2 
      inhibitors are associated with a low risk of hypoglycemia, except when used with 
      agents known to be associated with a higher risk of hypoglycemia, such as 
      sulfonylureas or insulin. CONCLUSIONS: The unique renal-specific mechanism of 
      action and favorable efficacy and safety profile of SGLT2 inhibitors support 
      consideration of these antidiabetes agents as a treatment option for patients 
      with T2DM.
CI  - (c) 2015 The Author(s).
FAU - Vivian, Eva
AU  - Vivian E
AD  - School of Pharmacy, University of Wisconsin, Madison, Wisconsin (Dr Vivian) 
      eva.vivian@wisc.edu.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20151008
PL  - United States
TA  - Diabetes Educ
JT  - The Diabetes educator
JID - 7701401
RN  - 0 (Benzhydryl Compounds)
RN  - 0 (Blood Glucose)
RN  - 0 (Glucosides)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Insulin)
RN  - 0 (SLC5A2 protein, human)
RN  - 0 (Sodium-Glucose Transporter 2)
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
RN  - 0SAC974Z85 (Canagliflozin)
RN  - 1ULL0QJ8UC (dapagliflozin)
RN  - HDC1R2M35U (empagliflozin)
MH  - Benzhydryl Compounds/pharmacology
MH  - Blood Glucose/drug effects
MH  - Canagliflozin/pharmacology
MH  - Diabetes Mellitus, Type 2/blood/complications/*drug therapy
MH  - Drug Therapy, Combination
MH  - Glucosides/pharmacology
MH  - Humans
MH  - Hyperglycemia/drug therapy/etiology
MH  - Hypoglycemia/chemically induced
MH  - Hypoglycemic Agents/*pharmacology
MH  - Insulin/therapeutic use
MH  - Kidney/drug effects/metabolism
MH  - Sodium-Glucose Transporter 2
MH  - *Sodium-Glucose Transporter 2 Inhibitors
EDAT- 2015/10/10 06:00
MHDA- 2017/01/20 06:00
CRDT- 2015/10/10 06:00
PHST- 2015/10/10 06:00 [entrez]
PHST- 2015/10/10 06:00 [pubmed]
PHST- 2017/01/20 06:00 [medline]
AID - 0145721715607643 [pii]
AID - 10.1177/0145721715607643 [doi]
PST - ppublish
SO  - Diabetes Educ. 2015 Dec;41(1 Suppl):5S-18S. doi: 10.1177/0145721715607643. Epub 
      2015 Oct 8.